Announcements Trials

Browse Landscape

Status

Sponsor Class

Study Type

Observational 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 7 Prostatic Neoplasms 2 Neoplasms 2 Lung Neoplasms 2 Urinary Bladder Neoplasms 1 Precursor Cell Lymphoblastic Leukemia-Lymphoma 1 Peripheral Nervous System Diseases 1 Pancreatic Neoplasms 1 Ovarian Neoplasms 1 Nasopharyngeal Carcinoma 1 Multiple Myeloma 1 Lymphoma, Non-Hodgkin 1 Leukemia, Myeloid, Acute 1 Gastroesophageal Adenocarcinoma 1 Depression 1 Carcinoma, Transitional Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Anxiety Disorders 1

Interventions

Rituximab 344 Cyclophosphamide 317 fludarabine phosphate 142 Etoposide 139 Peripheral Blood Stem Cell Transplantation 124 fludarabine 112 Filgrastim 112 Mycophenolic Acid 98 Melphalan 98 Whole-Body Irradiation 90 Vincristine 90 Busulfan 87 Cytarabine 85 Doxorubicin 79 Cyclosporine 76 Tacrolimus 75 Radiotherapy 75 Prednisone 73 Bendamustine Hydrochloride 72 Granulocyte Colony-Stimulating Factor 66 Methotrexate 65 Antilymphocyte Serum 56 Carmustine 54 Dexamethasone 50 Gemcitabine 48 Lenalidomide 46 Bortezomib 43 venetoclax 41 ibritumomab tiuxetan 37 obinutuzumab 36

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

Clinical Trials

1 trials

Recent Start date Enrollment

Lymphoma, Non-Hodgkin × Single Person × Clear all

NCT06008691 2025-12-29

FIL_MAB

Fondazione Italiana Linfomi - ETS

Lymphoma, Non-Hodgkin

Data powered by HemOnc (CC BY 4.0) Colophon ⚡